bioLytical Applauds Ontario's Commitment to 60-Second HIV Testing

HIV testing commences this fall at fifty sites, including 24 new HIV testing sites, primarily in northern and rural Ontario. bioLytical applauds Ontario's commitment to rapidly seeking out people infected with HIV and attending to those requiring treatment.

"This is a good day for every resident of Ontario," says Rick Galli, Chief Technical Officer, bioLytical, who holds Health Canada approval for their INSTI(TM) HIV-1 Rapid Antibody Test. "The Ontario government is aggressively pursuing the prevention and treatment of AIDS, both in the urban setting and in rural and remote Ontario. Rapid, point-of-care HIV testing will get the results and appropriate counselling to Ontario residents in a timely fashion in their own communities."

Carl Roy, CEO, bioLytical states, "We salute Ontario for their leadership and look forward to working with other provinces to expand this model." Roy believes: "Canada could quickly provide world leadership in their approach to the prevention and treatment of HIV. This is a great day for people who are at risk of the disease."

ABOUT INSTI(TM) HIV-1 RAPID ANTIBODY TEST

INSTI is a highly effective and reliable rapid HIV test that detects the presence of antibodies to HIV in whole blood, serum or plasma in 60 seconds. It has a 99.96% accuracy rate, as demonstrated in extensive clinical trials carried out in multiple centers across Canada. To further ensure INSTI maintains its high quality, it is manufactured in Canada under strict controls in a state-of-the-art ISO accredited facility. INSTI is the only HIV kit approved by Health Canada for point-of-care testing.

ABOUT BIOLYTICAL(TM) LABORATORIES

bioLytical Laboratories (Inc.) is a leading developer and manufacturer of diagnostic tests for global health care markets. The company produces the highly accurate and reliable INSTI kit; the only rapid HIV test kit approved by Health Canada for use in a point-of- care setting, such as a doctor's office or hospital. bioLytical is a privately owned company with headquarters and state-of-the-art manufacturing facility located in Richmond, British Columbia, with offices in United Kingdom and Uganda, Africa. For more information about bioLytical and INSTI, please visit www.biolytical.com.

This news release is not, and under no circumstances is to be construed as, an advertisement, solicitation or offering of securities of bioLytical(TM) Laboratories. The statements made in this news release may contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations.

Website: www.biolytical.com